Latest filing published 15 Jun 2023 for Aridis Pharmaceuticals, Inc..
Insider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
Hasan Jafri: trading record in brief
This profile gathers the share dealings of Hasan Jafri in Aridis Pharmaceuticals, Inc., where the filings describe the role as senior executive. We count 4 filings; the first trade dates from 3 September 2021 and the latest from 5 June 2023.
Every open-market trade on record is a purchase: 3 purchases worth €18k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 option exercise.
A typical purchase (the median) is worth €6,976.
Most recently, on 15 June 2023, the filings show an option exercise in Aridis Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,887 days ago, on 8 September 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Hasan Jafri
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 sharesCommon StockSEC:0001493152-23-021476:0
- 3,009 shares@ €3.4943100.0% of flowCommon StockSEC:0001104659-21-113792:0Canonical exit: 2 Dec 2021 (T+90)
2 of 2 declarations